Among the three acyl-CoA synthetase short-chain family members (ACSS), ACSS3 is poorly characterized. To characterize ACSS3, we performed molecular cloning and protein expression of rat acss3 and determined its intracellular localization, tissue distribution, and substrate specificity. Transient expression of rat ACSS3 in HeLa cells resulted in a 10-fold increase of acetyl-CoA synthetase activity compared with that in control cells. The acss3 transcripts are expressed in a wide range of tissues, with the highest levels observed in liver tissue followed by kidney tissue. Subcellular fractionation using liver tissue showed that ACSS3 is localized into the mitochondrial matrix. Among the short-chain fatty acids examined, recombinant ACSS3, purified from Escherichia coli cells transformed with the plasmid containing rat acss3, preferentially utilized propionate with a K M value of 0.19 mM. Knockdown of acss3 in HepG2 cells resulted in a significant decrease of ACSS3 expression level and propionyl-CoA synthetase activity in cell lysates. Levels of ACSS3 in the liver and the activity of propionyl-CoA synthetase in the mitochondria were significantly increased by fasting. These results suggested that ACSS3 is a liver mitochondrial matrix enzyme with high affinity to propionic acid, and its expression level is upregulated under ketogenic conditions. Keywords: molecular cloning/propionate metabolism/ propionyl-CoA synthetase/subcellular fractionation/ substrate specificity.
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Short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate have been shown to exert various beneficial health effects. In mammals, SCFAs are mainly produced by anaerobic microbiota in the gut as a byproduct of dietary fiber fermentation. After absorption by host colonocytes, SCFAs travel via the portal vein to the liver, where a portion of SCFAs is absorbed; the remaining portion is secreted into the blood stream and travels to the peripheral tissues. In these peripheral organs, SCFAs are thought to be utilized as an energy source (1) . Recently, G-protein coupled receptors FFAR2 and FFAR3 (also called GPR43 and GPR41, respectively) were identified as SCFA receptors and the biological functions of SCFAs through these receptors were revealed (2) . For instance, SCFAs are involved in the regulation of lipid and glucose metabolism (1, 3) . SCFAs have important roles not only as ligands of SCFA receptors, but also as precursors of metabolic intermediates. SCFAs are enzymatically converted into CoA adducts by the acyl-CoA synthetase short-chain family members (ACSS). In mammalian genomes, acss1, acss2, and acss3 have been reported as acss family member genes (46). While ACSS1 and ACSS2 have been well characterized, ACSS3 still needs further characterization.
ACSS1 is a mitochondrial matrix enzyme that has a high specificity for acetate (K M 0.06 mM) (5) . Acss1 is highly expressed in heart, skeletal muscle, and brown adipose tissue and its expression is strongly induced by fasting (5) . In skeletal muscles of acss1-deficient mice, the ATP levels measured during fasting are reduced of 50% compared to skeletal muscles of control mice. Moreover, acss1-deficient mice are hypothermic when maintained on a low-carbohydrate diet (7) . These findings indicate that ACSS1 is involved in thermogenesis under ketogenic conditions, using acetate as a vital fuel when carbohydrate availability is insufficient.
Acss2 is broadly distributed and highly expressed in liver, kidney, and heart (4); its expression is regulated by sterol regulatory element-binding proteins, the same ones that also regulate cholesterol and unsaturated fatty acid synthesis (4, 8, 9) . These studies underline an involvement of ACSS2 in lipid synthesis. Acss2 expression in liver and skeletal muscle is downregulated under ketogenic conditions (5, 9) . Similarly to ACSS1, ACSS2 has high specificity for acetate (K M 0.07 mM) (4); yet, it has a different subcellular localization than ACSS1 as it localizes in the cytoplasm and nucleus (10, 11) . Nuclear localization of the enzyme results in the generation of acetyl-CoA in the nucleus, which may play a role in acetylation of histones (11) and transcription factors (12) . Recently, it was reported that ACSS2 expression is upregulated in cancer cells, and the enzyme promotes acetate utilization as a nutritional source and maintains cancer cell growth under conditions of metabolic stress where other carbon sources cannot be used (13) .
Among ACSSs, the enzyme encoded by acss3 is poorly characterized. The acss3 gene was first identified in the human genome based on refined conserved sequence motifs of acyl-CoA synthetases, and its predicted amino acid sequence was thought to be an ACSS homolog (6) . The gene was found not only in humans but also in other mammals and zebrafish. Human ACSS3 has 32.9% and 31.8% amino acid identity with both human ACSS1 and ACSS2, respectively. ACSS3 is thought to distribute in mitochondria as judged from its deduced amino acid sequence, however, its substrate specificity, intracellular localization, tissue distribution, and biological significance have not been previously reported. Therefore, the aim of this study is to characterize ACSS3. For this purpose, we performed molecular cloning and protein expression of rat acss3 and determined its intracellular localization, tissue distribution, and substrate specificity. Here, we demonstrate that ACSS3 is a mitochondrial matrix enzyme in the liver that has affinity with propionic acid, whose expression is upregulated by fasting.
Experimental Procedures
Materials HeLa (JCRB9004) and HepG2 (JCRB1054) cells were obtained from JCRB cell bank (Japan). The anti-myc antibody (017-21871), anti-a-tubulin antibody (017-25031), and anti-b-actin antibody (013-24553) were obtained from Wako Pure Chemical Industries (Osaka, Japan). Anti-ACSS1 antibody (ab101570) and Alexa488-labeled anti-mouse IgG antibody were purchased from Abcam (Cambridge, UK) and Life technologies, respectively. Anti-ACSS3 antibody (HPA039353) and anti-SARDH antibody (AV42344) were purchased from Sigma-Aldrich (MO, USA). Anti-ACSS1 antibody (SC-85255), anti-SP1 antibody (SC-14027), and HRP-labeled second antibodies were obtained from Santa Cruz Biotechnology (TX, USA). Anti-ACSS2 (#3658), anti-VDAC (#4661), anti-COX IV (#4850), and anti-catalase (#12980) was purchased from cell signaling technology (MA, USA). We confirmed that anti-ACSS3 antibody (HPA039353) reacted with recombinant ACSS3 but not with recombinant ACSS1 and ACSS2 proteins (Supplementary figure 1) . Substrates used in acyl-CoA synthetase assay were purchased from Wako Pure Chemical Industries. All other reagents and chemicals were of the highest purity available.
Experimental animals
SpragueDawley (SD) rats were maintained at $25 C under 12-h lightdark cycle. They were supplied with a standard laboratory animal diet (CE-2, Nihon Clea Co., Tokyo, Japan) and tap water ad libitum. Care and use of the rats in this study followed the guidelines of Okayama Prefectural University and the laws and notifications of the Japanese government.
Cloning of the cDNA encoding rat acss3 To obtain a DNA fragment encoding rat ACSS3, a PCR amplification was performed using following primers based on the provisional acss3 nucleotide sequence (XM_006241302) on RGSC Genome Assembly v5.0; the sense primer, 5 0 -TGGAAGGGATGCTCAAC ATT-3 0 , and antisense primer, 5 0 -GGGCCACCAGACTAACTA CAC-3 0 were used for PCR with the cDNA library of a rat liver as a template in an iCycler (Bio-Rad, CA, USA) using PrimeSTAR MAX DNA polymerase (Takara Bio, Shiga, Japan). Next, an amplified PCR product (3 0 fragment) was sequenced. Further 5 0 -rat acss3 cDNA fragments were obtained by reverse transcription PCR from rat liver mRNA by using 5 0 /3 0 RACE kit, 2nd Generation (Roche, Mannheim, Germany) according to the manufacturer's protocol. The specific antisense primers were designed based on the nucleotide sequence of 3 0 fragment, and used for 5 0 -RACE, 5 0 -TCCTGCTTGT CCTGGTGG-3 0 , for 1st PCR and 5 0 -CACGCAGTCATGTGACT G-3 0 , for 2nd PCR. Obtained 5 0 -RACE fragment and 3 0 fragment were linked by overlap extension PCR to obtain cDNA containing whole ORF of rat acss3. Then PCR was performed using a sense primer with an EcoRI site (5 0 -CCGAATTCATGAAGCCCTCCTG GTTG-3 0 ), an antisense primer with an XhoI site and a disrupted stop codon (5 0 -CGCTCGAGCAAAGCCTGCTTCAGTAC-3 0 ), and the linked PCR products as template. The PCR product was cloned into pcDNA3.1/myc-His(+) (Thermo Fisher Scientific) to generate pcDNAratAcss3MycHis. With the same procedure the PCR products obtained using antisense primer with stop codon was cloned into the vector to generate pcDNAratAcss3.
Expression and purification of recombinant ACSS3
Based on PSORT II prediction, the ORF corresponding to mature rat ACSS3, ratÁ48ACSS3, (from 49th amino acids residues) with mycHis tag was cloned into pCold IV vector (Takara Bio) by PCR amplification using a sense primer with a SacI site (5 0 -CCGAGCTCCTGA CCACAAGCAGCGGT-3 0 ), an antisense primer with an EcoRI site (5 0 -CCGAATTCTAGAAGGCACAGTCGAGG-3 0 ), and pcDNA ratAcss3 as a template to generate pColdratÁ48ACSS3. To express recombinant ratÁ48ACSS3 E. coli HST08 competent cells (Takara Bio) were transformed with pColdratÁ48ACSS3. Transformed HST08 cells were grown to an A 600 nm = 0.4, then chilled at 15 C for 30 min. After adding IPTG (1 mM) to the culture, the recombinant proteins were induced at 15 C for 12 h. 6Â His-tagged proteins were purified by using His Bind Resin (Merck Millipore, Darmstadt, Germany) according to manufacturer's protocol. Binding proteins were eluted with elution buffer [0.5 M NaCl, 20 mM TrisHCl, pH 8, 0.5 M imidazole, 0.1% Triton X-100, and protease inhibitor cocktail (TOYOBO, Osaka, Japan)]. The elution containing purified proteins were used for the measurement of acyl-CoA synthetase activities. Under our experimental conditions 0.5 M imidazole did not interfere with the enzyme activities.
Cell culture and transfection
HeLa and HepG2 cells were grown in a humidified incubator at 37 C and 5% CO 2 in DMEM supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin, and 100 units/ml penicillin. cDNA and siRNA transfection was carried out using TransIT-X2 Dynamic Delivery System (Mirus Bio LLC, WI, USA) and Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific), respectively, according to the manufacturer's instructions. Sequence of siRNA duplex for human acss2 and acss3 (purchased from SIGMA genosys Japan, Tokyo, Japan) are as follows: acss2 sense, 5 0 -GAAGUUUCCUGGAUACUAUTT-3 0 and antisense, 5
0 -AUAGUAUCCAGGAAACUUC-3 0 ; acss3 sense, 5 0 -GU UUGUGGAAGGAAUGCUUTT-3 0 and antisense, 5 0 -AAGCAU UCCUUCCACAAACTT-3 0 .
Immunocytochemistry Transfected cells were cultured on glass coverslips. After 24 h post transfection, cells were labeled with MitoTracker Red CM-H 2 Xros (Thermo Fisher scientific) according to the manufacturer's instructions. Then the cells were fixed with 4% paraformaldehyde in PBS for 10 min. After washing with PBS, cells were incubated in 50 mM glycine/PBS for 5 min. After a second wash with PBS, cells were permeabilized with PBS containing 0.1% Triton X-100 (PBST) and then cells were blocked in PBST containing 3% bovine serum albumin (BSA) (blocking buffer) at room temperature for 1 h. The samples were incubated with an anti-myc antibody diluted 1:200 with blocking buffer at room temperature for 2 h followed by incubation with Alexa488-labeled anti-mouse IgG antibody and Hoechst 33,342 at room temperature for 1 h. Samples were observed with a confocal laser-scanning microscope (FLUOVIEW FV1000, Olympus, Tokyo, Japan).
Preparation of the cell lysates from cultured cells
To prepare cell lysates, cells were scraped off and collected by centrifugation. The cell pellets were washed with PBS, suspended, and sonicated in lysis buffer (20 mM TrisHCl, pH 8.0, containing 0.1% Triton X-100, 1 mM EDTA, 1 mM DTT, and protease inhibitor cocktail). The lysates were centrifuged at 20,400Â g for 1 min, and the supernatants were collected, and used in following experiments.
Measurement of acyl-CoA synthetase activities
The activity of purified protein or cell lysates was measured using the hydroxylamine method to measure fatty acid-, ATP-, and CoA-dependent formation of acyl-CoA species that were detected as hydroxamate described previously (14) . Briefly, the sample was added into the reaction mixture (0.1 ml) which contains 100 mM hydroxylamine, 50 mM TrisHCl, pH 8.0, 1 mM substrate, 10 mM MgCl 2 , 10 mM ATP, 2 mM DTT, and 1 mM CoA. The reaction mixture was incubated at 37 C for indicated period. The reaction was stopped by the addition of ferric chloride reagent (0.1 ml of 10% FeCl 3 in 2 M HCl, 3.3% trichloroacetic acid). After a centrifugation of the reaction mixture at 20,400 Â g for 1 min, the color generated was measured at 540 nm. Samples without the enzyme served as a blank. Standard curve was constructed with formation of acetylhydroxamate by acetyl phosphate (04 mM). Protein content of samples was determined by Bradford assay with BSA as a standard. The specific activity was given as nmol min À 1 mg protein À 1 in the assay using cell lysate or as mmol min À 1 mg protein À 1 in the assay using purified recombinant protein.
Quantitative reverse transcription PCR analysis
The total RNA was extracted from rat tissues using Sepasol RNA I super G (Nacalai tesque, Kyoto, Japan), and treated with RNase inhibitor (TOYOBO) to avoid degradation of RNA. Then the sample was reverse-transcribed and contaminating genomic DNA was degraded using PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio) according to the manufacturer's instructions. To determine mRNA expression levels, real-time quantitative PCR analyses were performed by using the iQ5 real-time PCR detection system (Bio-Rad) with KAPA SYBR Õ FAST qPCR Kits (Kapa Biosystems, MA, USA). The primer sequences used for the amplification were described as follows: rat acss1 forward, 5
0 -ACTGTCTG GGACTGCGACTT-3 0 , and reverse 5 0 -TCCTCACTTCTGTCCCA GGT-3 0 ; rat acss2 forward, 5 0 -GGTGCTCAGAACTTGACGTG-3 0 , and reverse 5 0 -GGCATGGGGTTTTCCAGTA-3 0 ; rat acss3 forward, 5
0 -TGGAAGGGATGCTCAACATT-3 0 , and reverse 5 0 -CCA GCCAGCTTAGAGACCTG-3 0 ; rat actb forward, 5 0 -GGAGATTA CTGCCCTGGCTCCTA-3 0 , and reverse 5 0 -GACTCATCGTACTC CTGCTTGCTG-3 0 . Gene expressions were normalized to actb expressions. Data is expressed as 2ˆdCT. All PCR products were identified and confirmed by DNA sequencing and melting temperature.
Subcellular distribution of ACSS3 in the liver
The livers of 6-weeks-old SD-rats were removed and homogenized using a Potter-Elvehjem-type homogenizer in ice-cold 0.25 M sucrose. All isolation steps were carried out at 4 C. Nuclei fraction was collected by centrifugation of the homogenate at 600 Â g for 10 min, then the further separation of nuclei fraction was performed by a sucrose density centrifugal separation method at 12,000 Â g for 30 min to remove debris and unbroken cells. The mitochondrial fraction was prepared by centrifugation of the post-nuclear supernatant at 8,000Â g for 10 min, and then the mitochondrial pellet was suspended in 0.25 M sucrose containing 10 mM Tris-HCl, pH 7.4. The suspension was further centrifuged in a 1.11.6 M sucrose density at 82,000 Â g for 200 min, resulted in the purified mitochondrial fraction. To separate the mitochondrial inner membrane and matrix, after standing the mitochondrial fraction in 10 mM Tris-HCl buffer, pH 8.0 containing 0.25 M sucrose and 3 mg/mL digitonin with continuous stirring on ice for 20 min, the suspension was centrifuged at 9,500 Â g for 15 min as described in previous report (15) . The pellet was suspended in the lysis buffer described in 'Preparation of the cell lysates from cultured cells' to obtain the inner membrane and matrix fraction of mitochondria. In order to obtain outer membrane fraction of mitochondria, the supernatant was centrifuged at 105,000 Â g for 60 min and the resulting pellet was suspended in the lysis buffer. Preparation of soluble and insoluble fraction of mitochondria was performed using the carbonate extraction method as described in (16, 17) . To separate the peroxisome, light mitochondrial fraction was prepared by differential centrifugation of the postnucleus fraction and the resulting pellet was resuspended into 10 ml of 67% (v/v) Percoll (GE Healthcare, Buckinghamshire, UK), 0.15 M NaCl solution and centrifuged at 105,000 Â g for 60 min. The peroxisome fraction containing higher amount of catalase was obtained from the top of the supernatant (0.3 ml).
Immunoblot Protein content was determined by Bradford assay with BSA as a standard. SDS-PAGE was carried out according to the method of Laemmli (18), and proteins on the gel were transferred onto a polyvinylidene difluoride membrane (Merch, Darmstadt, German). After treatment with 3% BSA in Tris-buffered saline that contained 0.1% Tween 20 (TBST) for 1 h, the membrane was incubated with the primary antibody diluted in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO) overnight at 4 C. The dilution rate of primary antibodies was decided according to manufacturer's recommendation. After three washes with TBST, the membrane was incubated with an HRP-conjugated secondary antibody for at least 1 h. After other three washes with TBST, the chemiluminescent reaction was performed for 5 min with ImmunoStar LD (Wako Pure Chemical Industries) as recommended by the manufacturer, and chemiluminescent signals were visualized and quantified with ImageQuant LAS-4000 and Multi Gauge V3.2 analyzing software (Fujifilm, Tokyo, Japan).
Results

Molecular cloning of rat acss3
To characterize the enzyme encoded by acss3, we first cloned rat acss3 by PCR. PCR amplification was conducted using primers designed from the predicted acss3 sequence (XM_006241302) in a rat genome database, using rat liver cDNA as a PCR template. The nucleotide sequence of the obtained cDNA clone possessed an open reading frame (ORF) of 2,049 base pairs, encoding 683 amino acids. The putative amino acid sequence of the obtained clone matched with that of XP_006241364 encoded by the predicted acss3 gene. Finally, a cDNA clone encoding the rat acss3 ORF was subcloned into a pcDNA3.1/Myc-His(+) vector, to generate pcDNAratAcss3MycHis. Similarly, pcDNAratAcss3 was constructed with a cDNA clone that has rat acss3 ORF followed by a stop codon. The alignment of the deduced amino acid sequence from the nucleotide sequence and other rat ACSS homologues was shown in Fig. 1A . Rat ACSS3 shares 32.6% and 31.9% sequence identity with rat ACSS1 and rat ACSS2, respectively (Fig. 1B) . Analysis of rat ACSS3 subcellular localization using WoLF PSORT II predicted localization in the mitochondria (26.5%) followed by cyto_mito (cytosol or mitochondria, 16%), and suggested that rat ACSS3 is a mitochondrial enzyme like ACSS1 due to a mitochondrial targeting sequence at its N-terminus (amino acid residues 1-48) (Fig. 1A) .
Expression and intracellular localization of rat ACSS3 in HeLa and HepG2 cells To verify whether pcDNAratAcss3 encodes an acetylCoA synthetase, HeLa cells were transfected with pcDNAratAcss3, and acetyl-CoA synthetase activity in the cell lysates was measured. The activity in cell lysates of the transfectants was significantly higher (approximately 10-fold) compared with mock transfectants ( Fig. 2A) . Although there were limitations such that the transient over expression may result in artifacts, the results suggested that the cloned cDNA does indeed encode an enzyme with acetyl-CoA synthetase activity. The expressed ACSS3 and MycHis-tagged ACSS3 (ACSS3MycHis) showed 69-and a 72-kDa bands, respectively, after SDS-PAGE and visualization with an anti-ACSS3 antibody (Fig. 2B) . Considering the deduced molecular masses of ACSS3 and ACSS3 after mitochondrial signal peptide processing (74.7 and 69.8 kDa, respectively), we determined that expressed ACSS3 could be truncated by proteolytic processing. PSORT II analysis revealed that ACSS3 had a mitochondrial targeting sequence at its N-terminus and may localize in the mitochondria (Fig. 1A) . To investigate the intracellular localization of ACSS3, ACSS3MycHis was expressed in HeLa and HepG2 cells, and myc signals were observed under a confocal fluorescence microscope. The myc signals were observed in mitochondria in both cell lines, and this localization was confirmed by double staining with MitoTracker ( Fig. 2C and D) . These results suggested that ACSS3 is a mitochondrial enzyme that has acetate CoA ligase activity.
Tissue distribution of acss3 in rat
To assess the biological function of acss3, we next investigated the tissue distribution of acss1, acss2, and acss3 expression in rats. Quantitative PCR analysis revealed that acss1 mRNA expression registered the highest level in the heart, a relatively high level in kidney, and lower levels in skeletal muscle, spleen, and brain (Fig. 3A) . As seen in a previous study by Fujino et al., our analysis showed that the acss1 transcript was hardly detectable in the liver (5) . In contrast to acss1, acss2 mRNA expression was relatively high in the liver as wells as the heart (Fig. 3B) . The highest expression level of acss2 was shown in the kidney in accordance with previous studies (4, 9) . Unlike acss1 and acss2, the highest acss3 mRNA expression was detected in the liver, followed by the kidney (Fig. 3C) . These results suggest that acss3 may play a role in the liver where only slight levels of acss1 were seen.
Subcellular localization of ACSS3 in the liver
Since the data shown above suggest that ACSS3 is an acyl-CoA synthetase in liver mitochondria, we then investigated the subcellular distribution of ACSS3 in the liver by cell fractionation followed by immunoblotting using an anti-ACSS3 antibody. As expected, ACSS3 distributed in mitochondria as confirmed by cofractionation with voltage-dependent anion channel (VDAC), mitochondrial marker protein (Fig. 4A) . Because the mitochondrial fraction prepared by the method we used included peroxisomal proteins such as catalase (Fig. 4A) , it cannot be denied that ACSS3 distributes in the peroxisome. To examine the possibility, we separated the peroxisome from the light mitochondrial fraction of the liver by Percoll density gradient centrifugation. The resulting fraction included catalase but not ACSS3 (a 72 kDa band, Fig. 4A) . Furthermore, the signals of the tagged-ACSS3 expressed in the human cultured cells did not colocalized that of catalase in these cells (Supplementary Fig. 2 ). These results indicate that ACSS3 localizes predominantly in the mitochondria. Further fractionation of cellular organelles showed that ACSS3 distributed in the inner mitochondrial membrane or matrix fraction, as judged by cofractionation with sarcosine dehydrogenase (SARDH), a matrix marker protein (19) , and COXIV, an inner membrane marker protein, but not with VDAC, an outer membrane marker protein (Fig. 4B) . To determine whether ACSS3 is attached to the inner side of the membrane or is soluble in the matrix, we extracted mitochondria with sodium carbonate (16, 17) . ACSS3 was completely extracted by sodium carbonate treatment and exhibited a distribution pattern similar to the soluble matrix protein SARDH but different from the membrane protein VDAC (Fig. 4C) . These data indicated that ACSS3 is a soluble mitochondrial matrix enzyme in the liver.
Substrate specificity of recombinant rat ACSS3 Despite the preferential substrate of both ACSS1 and ACSS2 is acetate among short and medium chain fatty acids, these enzymes can also utilize propionate with lower affinities (4, 5) . To reveal the enzymatic properties of ACSS3, N-terminal truncated His-tagged recombinant rat ACSS3 (Á48ACSS3MycHis) was expressed in E. coli and purified with Ni-affinity beads. Purified recombinant rat ACSS3 showed a specific activity of 1.36 mmol min À 1 mg À 1 for acetate when the acetate concentration was 20 mM (Fig. 5A) . As determined by the Lineweaver-Burk plots, K M values for acetate, propionate, and butyrate were 5.4 ± 0.48, 0.19 ± 0.012, and 3.7 ± 0.12 mM, respectively (Fig. 5BD) . These values suggest that ACSS3 had a wider substrate specificity than ACSS1 or ACSS2 and preferred propionate as a substrate among SCFAs. No ACSS3 activity was detected using fatty acids with 5-8 carbon chains or 3-hydroxybutyrate as substrates under our experimental conditions (data not shown). Both ATP and CoA were required for ACSS3 activity (data not shown). These results indicate that the preferred substrate of ACSS3 is propionate among the short to medium chain fatty acids investigated.
Knockdown of acss3 in HepG2 cells
Since the data mentioned above suggest that ACSS3 is a mitochondrial matrix propionyl-CoA synthetase in the liver, we next investigated whether ACSS3 is the enzyme responsible for propionyl-CoA synthetase activity in hepatic cells. HepG2 cells, derived from human hepatocellular carcinoma, were transiently transfected with only acss2-and acss3-targeted siRNA or both siRNAs and then the cell lysates of transfectants were subjected to immunoblotting and enzyme activity assays. First, we examined the subcellular distribution of ACSS isoforms in the cells. ACSS2 was dominantly distributed in the cytosol fraction, whereas ACSS3 was in the mitochondrial fraction (Fig. 6A) as same as in the liver (Fig. 4A) . On the other hand, ACSS1 could not be detected under our experimental conditions. Knockdown of acss2 and acss3 by 50 nM siRNA specifically induced a significant reduction of each protein expression to approximately 57.4% and 48.2% of the negative control, respectively (Fig. 6B, C) . The acyl-CoA synthetase activities were measured in the transfectants lysate using acetate as substrates. These measures revealed a significant reduction of acetyl-CoA synthetase activity due to acss2 knockdown, but not acss3 knockdown (Fig. 6D) . On the other hand, the activity of propionyl- Fig. 3 Tissue expression of acss3 transcripts. Total RNA prepared from rat tissues (brain, cerebellum, heart, soleus muscle, gastrocnemius muscle, lung, spleen, liver, kidney) were reverse-transcribed. The products from three tissues were mixed and used as templates for quantitative real-time PCR to quantitate relatively mRNA expressions of acss1 (A), acss2 (B), and acss3 (C). Data represents the mean ± SE from three experiments.
CoA synthetase in the acss3-knockdown lysate was significantly reduced to 52% of the activity of negative control transfectant lysates, whereas that in the acss2-knockdown cells was not (Fig. 6F) . When butyrate was used as substrate, the butyryl-CoA synthetase activities in the lysates were not influenced by either acss2 or acss3 knockdown (Fig. 6F) . Moreover, the activities of acetyl-CoA and propionyl-CoA synthetase in the lysates of double knockdown cells were significantly lower than that of negative control cells (Fig. 6D and  E) . These results indicate that ACSS3, and not ACSS2 is the enzyme responsible for the propionyl-CoA synthetase activity in hepatic cells.
Induction of ACSS3 expression under ketogenic conditions
Previous studies demonstrated that fasting induces a marked increase in acss1 mRNA expression in heart and skeletal muscle tissue (5). In contrast, fasting reduces acss2 mRNA expression in the liver, adipose, and skeletal muscle tissue (5, 9, 20) . To determine the biological function of ACSS3 in the liver, we examined the effects of fasting on the expression level of ACSS3. Since the expression of acss2 and acss3 but not acss1 was observed in rat liver (Fig. 3) , ACSS2 and ACSS3 expression were investigated by immunoblotting. After 48 h of fasting, a $64% reduction of ACSS2 was Fig. 4 Subcellular distribution of ACSS3 in rat liver. (A) Nucleus, mitochondria, cytosol, and peroxisome fraction of the liver were fractionated by centrifugation as described under "Experimental procedures." Cellular fractionation was confirmed by immunoblot with antibodies specific for the nucleic transcriptional factor SP1 (42), mitochondrial matrix protein SARDH (19) , mitochondrial outer membrane protein VDAC, mitochondrial inner membrane protein COXIV, cytosolic protein a-tubulin, and peroxisomal protein catalase. (B, C) Submitochondrial fractionations were carried out by centrifugation of the mitochondrial fraction (B) or by extraction with sodium carbonate (C). VDAC and SARDH were utilized as the marker proteins for mitochondrial membrane fraction and matrix fraction, respectively. observed (p50.05, Fig. 7A and B) in accordance with a previous study (9) , and a 1.8-fold induction of ACSS3 was seen in the liver (p50.05, Fig. 7A and  C) . In addition, we measured acetyl-CoA synthetase activity in the cytosol and propionyl-CoA synthetase activity in the mitochondria prepared from each liver of different rats. Because ACSS2 (4, 5) and ACSS3 (Fig. 5) can convert both acetic acid and propionic acid into CoA adduct, the cytosol and mitochondria of the liver were fractionated to separate the activity of these ACSS isoforms. The acetyl-CoA synthetase activity in the cytosol of the liver from fasted rats was significantly less than that from control rats (Fig. 7D) , whereas the propionyl-CoA synthetase activity in the mitochondria of the liver from fasted group was significantly higher than that from control group (Fig.  7E) , showing good agreement with the results of immunoblotting ( Fig. 7B and C) . These results suggest that ACSS3 is induced in the liver under ketogenic conditions.
Discussion
In this study, we performed molecular cloning and partial characterization of ACSS3, never performed before, and revealed that ACSS3 is a mitochondrial matrix propionyl-CoA synthetase in the liver and its expression is upregulated by fasting.
To characterize ACSS3, we expressed rat ACSS3 in human cell lines and calculated the molecular mass of the exogenously expressed proteins. In HeLa cells, the endogenous ACSS3 was scarcely expressed as observed by immunoblotting with an anti-ACSS3 antibody under our experimental conditions (Fig. 2B , mock lane), whereas exogenous ACSS3 and tagged-ACSS3 were expressed as 69-kDa and a 72-kDa proteins, respectively, on SDS-PAGE (Fig. 2B , middle and right lane). These sizes were smaller than the molecular masses predicted from the amino acid sequence, suggesting that ACSS3 is truncated after translation. In this study the N-terminal amino acid residues of the mature ACSS3 was not determined. Despite that, the cleavage site estimated by PSORT II program is likely accurate (Fig. 1A) , as the molecular mass of the estimated mature ACSS3 (69.8 kDa) corresponds with that of the expressed protein (69 kDa, Fig. 2B middle lane). In addition, purified recombinant Á48ACSS3 MycHis protein showed a 72-kDa band in an immunoblot (Supplementary figure 1) , which size matches with that of ACSS3MycHis expressed in HeLa cells using pcDNAratACSS3MycHis as an expression vector (Fig. 2B right lane) and the purified protein expressed by E. coli cells showed enzymatic activity (Fig. 5) .
As predicted by the PSORT II program, ACSS3 localized to the mitochondria in human cultured cells ( Fig. 2C, D) and rat liver (Fig. 4) . ACSS1 is distributed in the mitochondria (17) and ACSS2 is in the cytosol and nucleus (10, 12) . Since ACSS3 is a mitochondrial matrix enzyme with acetyl-CoA synthetase activity ( Fig. 2A and 4A ) and the mitochondrial matrix protein ACSS1 is scarcely expressed in the liver (Fig. 3A) , ACSS3 might be an alternative enzyme for ACSS1 in the liver, except that their substrate specificities are markedly different. ACSS1 and ACSS2 have a similar substrate preference, which is a high affinity for acetate (K M 0.06 and 0.07 mM, respectively) and a lower affinity for propionate (K M 4.1 mM and 3.4 mM, respectively) (4, 5) . On the other hand, under our experimental conditions (Fig. 5 ), ACSS3 has a high affinity for propionate (K M 0.19 mM), but a lower affinity for acetate (K M 5.4 mM). We also investigated the substrate specificity of recombinant ACSS1 and ACSS2, finding that the K M values for acetate and propionate were similar to those found in previous studies mentioned above (data not shown). Therefore, among the three acyl-CoA synthetase short-chain family members, ACSS3 is unique in its substrate specificity and tissue distribution, that is, ACSS3 is a mitochondrial matrix propionyl-CoA synthetase in the liver. Under our experimental conditions, liver mitochondrial matrix extract showed acyl-CoA synthetase activity with a K M value for acetate of 6.2 mM and 0.80 mM for propionate (Supplementary figure 3) , which are similar to ACSS3 K M values (Fig. 5) . Knockdown of ACSS3 in HepG2 cells resulted in a reduction of propionyl-CoA synthetase activity but not acetyl-CoA synthetase or butyryl-CoA synthetase in the lysate (Fig. 6 ). These data support the hypothesis that ACSS3 is a propionyl-CoA synthetase in liver mitochondria. To the best of our knowledge, this is the first report of a gene responsible for propionyl-CoA synthetase activity, except for the bacteria propionyl-CoA synthetase prpE (21) . The predicted amino acid sequence of Salmonella prpE shares 36.4% of identity with ACSS3, which is higher than its shared identity with ACSS1 or ACSS2 (33.9% and 33.1%, respectively. Fig. 1B) . Furthermore, the substitution of Val388 and Val366 to Ala on Methanothermobacter thermautotrophicus and Salmonella enterica acetyl-CoA synthetases, the amino acid residues corresponding to Val409 on rat ACSS1, Val448 on rat ACSS2, and Ala420 on rat ACSS3 (Fig. 1A) , resulted in a significant shift in substrate preference from acetate to propionate, which strongly supports our hypothesis (22, 23) . Although among the substrates investigated in this study the most preferable substrate for ACSS3 was propionate, the possibility that other compounds are more preferable for ACSS3 remains unexplored.
SCFAs, including propionate, are mainly produced by gut microbiota in the cecum and large intestine from non-digestible carbohydrates such as plant cell wall polysaccharides, oligosaccharides, and resistant starch. These compounds are then absorbed by the host colonocytes on the apical membrane. The portion of SCFAs that is not utilized by the colonocytes is transported across the basolateral membrane into the portal blood. Isotope studies on human children who suffered from propionic acidemia, a propionate metabolism disorder, showed that gut microbiota produce $0.05 mmol kg body weight À 1 h À 1 propionate (24). The concentration of propionate in the gut is estimated to be 1428 mM in the proximal colon and 0.41.4 mM in the distal colon, depending on diet (25) . It is estimated that 95% of the SCFAs produced by microbiota are rapidly absorbed by the host colonocytes while the remaining 5% is secreted in the feces (1, 25, 26) . The concentration of propionate in the portal venous, hepatic venous, and peripheral blood is estimated to be 88.3, 21.2, and 5 mM, respectively (27) . These studies suggest that a significant fraction of propionate produced by gut microbiota could be absorbed and metabolized by the host liver to prevent high propionate concentration in the blood (28) , which otherwise would cause propionic acidemia. In mammals, propionate is converted into propionyl-CoA by propionyl-CoA synthetase (which has not yet been purified and identified) in the liver mitochondrial matrix and kidney cortex (29) . Then, propionyl-CoA is converted into D-methylmalonyl-CoA by propionylCoA carboxylase (30) , isomerized to L-methylmalonylCoA by methylmalonyl-CoA epimerase (31) , and rearranged to yield succinyl-CoA by methylmalonyl-CoA mutase (32, 33) . Succinyl-CoA then enters the TCA Fig. 7 Effects of fasting on the expression level of ACSS3 in the liver. Proteins were extracted from the liver of each nonfasted control rats (control, n = 3) and rats fasted for 48 h (fasted, n = 3) and were subjected to immunoblotting (A). Each lane represented a different rat liver lysate. Expression levels of ACSS2 (B) and ACSS3 (C) were quantified and corrected by that of a-tubulin. Values represent mean ± SE shown as relative expression normalized to the value of control, n = 3 (D, E) The activity of acetyl-CoA synthetase in the cytosol (D) and propionyl-CoA synthetase in the mitochondria (E) prepared from each liver of different rats were measured as described under 'Experimental procedures.' Values represent mean ± SE shown as specific activity (mmol min À 1 g tissue À 1 ), n = 4 (D, E). Asterisk indicates significance at p50.05, Student's ttest.
cycle and is converted to oxaloacetate, which can be utilized as either an energy source or the precursor of gluconeogenesis (34) . Especially in ruminants, propionate significantly contributes to glucose synthesis (35, 36) . In other mammals, propionate can also contribute to gluconeogenesis in the liver and kidney (3739). ACSS1, which can activate propionate, is less expressed in the liver mitochondria (Fig. 4) (5) and the knockdown of ACSS3 in HepG2 hepatoma cells resulted in decreased CoA ligase activity to propionate but not acetate or butyrate (Fig. 6) . Therefore, the probable enzyme responsible for propionate activation in liver mitochondria is ACSS3. Analysis of the acss3 expression pattern in tissues revealed that the transcripts were expressed predominantly in the liver and kidney, the only organs for gluconeogenesis (Fig.  3C) , and fasting resulted in increased expression of ACSS3 in the liver (Fig. 7A and C) . These results were supported by the recent work by Ellis et al. showing that the acss3 mRNA expression in the liver was significantly induced by fasting (20) . In conclusion, ACSS3 may be involved in the oxidation of propionate to generate energy and/or to supply a substrate for gluconeogenesis by activating propionate in the liver under ketogenic conditions. Although the detailed biological functions of ACSS3 should be addressed in a future study, our results might shed light on a part of the whole aspect of propionate metabolism that has not been elucidated.
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